Critical Review: Hero Technologies (OTCMKTS:HENC) versus Cellectar Biosciences (NASDAQ:CLRB)

Hero Technologies (OTCMKTS:HENC) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Volatility & Risk

Hero Technologies has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Hero Technologies and Cellectar Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hero Technologies	0	0	0	0	0.00
Cellectar Biosciences	0	2	2	0	2.50

Cellectar Biosciences has a consensus target price of $375.00, indicating a potential upside of 6,399.13%. Given Cellectar Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Hero Technologies.

Earnings & Valuation

This table compares Hero Technologies and Cellectar Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hero Technologies	N/A	N/A	-$540,000.00	N/A	N/A
Cellectar Biosciences	N/A	N/A	-$44.58 million	($19.91)	-0.29

Institutional & Insider Ownership

16.4% of Cellectar Biosciences shares are held by institutional investors. 0.2% of Hero Technologies shares are held by company insiders. Comparatively, 5.0% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Hero Technologies and Cellectar Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hero Technologies	N/A	N/A	N/A
Cellectar Biosciences	N/A	-486.67%	-150.57%

Summary

Cellectar Biosciences beats Hero Technologies on 5 of the 9 factors compared between the two stocks.

About Hero Technologies

Hero Technologies Inc. operates as an early-stage cannabis company. It focuses on the provision of BlackBox, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and the cultivation of large flowering plants and create increased harvest efficiencies. The company also intends to offer cannabis genetic engineering farmland for medical and recreational cannabis cultivation, production, distribution, packaging, and retail operations, as well as for dispensaries. The company is based in Dover, Delaware.

About Cellectar Biosciences

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.